Clinical trials
Heart Transplant Rejection clinical trials
Below are recruiting heart transplant rejection clinical trials, each written for real people, not researchers. We’re tracking 44 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07046910RecruitingPhase 2
MRI to detect lung rejection after transplant
This study uses a special MRI scan (called hyperpolarized gas MRI) to check for signs of lung rejection after a transplant. The goal is to see if the MRI can help detect rejection earlier and more safely than standard bronchoscopy alone.
Charlottesville, VirginiaAges 18–80 - NCT07053488RecruitingPhase 1/Phase 2
Gene-edited liver transplant to lower rejection risk
This trial tests a liver transplant using a donor organ that has been gene-edited to reduce the risk of rejection. It may help people who need a liver transplant and are not a perfect tissue match with their donor.
Beijing, ChangpingAges 16–85 - NCT04656080Recruiting
Test heart and lung exercise capacity after transplant
This study uses a treadmill or stationary bike test to measure how well your heart and lungs work after a heart transplant. It may help researchers see whether this type of testing is safe and useful in transplant follow-up.
Dallas, TexasAges 18 years+ - NCT06532890Recruiting
Using microRNAs to personalize heart transplant medicines in children
This study is looking at heart transplant children (up to age 18) to see if measuring tiny molecules called microRNAs in the blood can help doctors personalize anti-rejection medicines. It aims to improve how we prevent rejection while reducing side effects.
Aurora, ColoradoAges Up to 18 years - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
Birmingham, AlabamaAges 18–75 - NCT06939751Recruiting
Testing microRNA levels to personalize heart transplant care
This trial is studying whether a blood test that measures small molecules called microRNAs can help doctors personalize the medicines used to prevent rejection after a heart transplant. If you qualify, you would help researchers learn how to better match immunosuppression to each patient's needs.
Los Angeles, CaliforniaAges 18–99 - NCT06089486Recruiting
New Heart Scan for Transplant Patients
This study investigates a new heart scan (called a cardiac PET) to detect early signs of blood vessel disease in heart transplant patients. If you had your transplant 2 to 10 years ago, this scan might be an alternative to the usual yearly checkup with an invasive procedure (angiogram).
Calgary, AlbertaAges 18 years+ - NCT07508787RecruitingPhase 2
Study comparing siplizumab to another drug for kidney transplant acceptance
This trial tests a new drug, siplizumab, to see if it helps the body accept a donated kidney better than a standard treatment. It is for people receiving a kidney transplant from a living or deceased donor.
Sacramento, CaliforniaAges 18–70 - NCT06801886Enrolling by invitationPhase 3
Silymarin for better kidney transplant success
This trial tests if adding silymarin (a milk thistle extract) to standard anti-rejection medicines helps protect the new kidney from damage. It may improve how well the transplanted kidney works over time.
MartinAges Any age - NCT04180085RecruitingPhase 2
Belatacept to protect kidneys in heart transplant patients
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
BordeauxAges 18 years+ - NCT05385432RecruitingPhase 3
Kidney transplant induction therapy for sensitized patients
This trial tests a specific “induction” treatment to help people who have stronger immune reactions from past sensitizing events during a kidney transplant. It may help improve how well the transplant works and how safely the immune system is managed.
ToursAges 18–79 - NCT00106925Recruiting
Long-term follow-up for people after stem cell transplant
This study follows people who are at least 3 years out from their first stem cell transplant to learn how they are doing long term. It may help improve future transplant care by tracking outcomes over time.
Bethesda, MarylandAges 7–80 - NCT06398457RecruitingEarly Phase 1
Darzalex Before Stem Cell Transplant for High-Risk Graft Failure
This trial tests giving a drug called Darzalex Faspro before the usual desensitization and a stem cell transplant for people at high risk of graft failure due to donor-specific antibodies. The goal is to prevent the transplant from failing.
Baltimore, MarylandAges 18 years+ - NCT06751602Enrolling by invitationPhase 2
Belumosudil to prevent kidney scarring after transplant
This trial tests whether a drug called belumosudil can reduce scarring in the kidney after transplant. Scarring can lead to kidney damage over time, and this study aims to stop that from happening.
Houston, TexasAges 18–75 - NCT05525507RecruitingPhase 1
Test early immune-tolerance treatment for matched kidney transplant patients
This Phase 1 study tests a treatment plan given after a kidney transplant to help the immune system stay calm and reduce the risk of rejection. Participants must have a well-functioning kidney transplant from a closely matched living donor and meet health and safety requirements.
Los Angeles, CaliforniaAges 18 years+ - NCT06794970Recruiting
Tissue study for chronic kidney transplant rejection
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
Bologna, BOAges 18 years+ - NCT06948097RecruitingPhase 1
Testing fostamatinib for lung transplant patients with donor-specific antibodies
This trial tests a new medicine called fostamatinib for people who have had a lung transplant and have developed donor-specific antibodies (DSA) on their lung. The goal is to see if this medicine is safe and can help prevent the body from rejecting the new lung.
Stanford, CaliforniaAges 18–99 - NCT07531966Recruiting
Blood Vessel Problems After Kidney Transplant Treatment
This study looks at treating narrowing or blockage of blood vessels in transplanted kidneys. If your transplanted kidney is showing signs of not working well and imaging shows a blocked vessel, this trial tests whether a procedure called angioplasty (opening the vessel with a tiny balloon) can help restore blood flow and improve kidney function.
AarhusAges 18 years+ - NCT03173937RecruitingPhase 1/Phase 2
Cord blood transplant for severe aplastic anemia
This study tests a special cord blood transplant that may help your body start making blood cells faster than a regular transplant. It is for people with severe aplastic anemia or related bone marrow failure who have not gotten better with other treatments.
Bethesda, MarylandAges 4–75 - NCT03520647RecruitingPhase 2
Haplo transplant for severe bone marrow failure using donor cells
This trial tests a stem cell transplant from a closely matched but not fully matched family donor (haploidentical), with chemotherapy after the transplant to help prevent graft-versus-host disease (GVHD). It may help people with severe aplastic anemia, certain MDS after transformation, or PNH when other treatments have not worked or are not available.
Bethesda, MarylandAges 4–75
Hear when a new Heart Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for heart transplant rejection?
- Yes. Clin2 currently lists 44 recruiting heart transplant rejection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a heart transplant rejection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a heart transplant rejection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.